(84 intermediate revisions by 4 users not shown) | |||
Line 16: | Line 16: | ||
<title>Home</title> | <title>Home</title> | ||
<!-- Bootstrap --> | <!-- Bootstrap --> | ||
− | + | <link rel="stylesheet" type="text/css" href="https://2017.igem.org/Template:Northwestern/CSS?action=raw&ctype=text/css" /> | |
<style> | <style> | ||
Line 66: | Line 66: | ||
<span style="color:#4C177D;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | <span style="color:#4C177D;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | ||
</span> | </span> | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | |||
</button> | </button> | ||
</div> | </div> | ||
Line 72: | Line 77: | ||
<div class="bgimg-2 w3-display-container" id="first"> | <div class="bgimg-2 w3-display-container" id="first"> | ||
− | <div style="padding: 10%;"> | + | <div style="padding: 5% 10%;"> |
− | <h3 style="color:white" class="w3-center w3-padding-large"> | + | <h3 style="color:white" class="w3-center w3-padding-large"><br><br>Engineering pathways for integrating functional Cas9 protein into OMVs </h3><br> |
<p style="padding-right: 10%; padding-left:10%; font-size:14px; color:white;" class="big"> Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.<br><br> | <p style="padding-right: 10%; padding-left:10%; font-size:14px; color:white;" class="big"> Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.<br><br> | ||
</p> | </p> | ||
− | <ul class="ch-grid" | + | <ul class="ch-grid" height="50%" style=padding:0;"> |
<li> | <li> | ||
<div class="ch-item ch-img-2"> | <div class="ch-item ch-img-2"> | ||
Line 92: | Line 97: | ||
<h3 class="ch-bubble">Project description</h3> | <h3 class="ch-bubble">Project description</h3> | ||
<p class="ch-bubble">Outer Membrane Vesicles<br> | <p class="ch-bubble">Outer Membrane Vesicles<br> | ||
− | <a class="ch-bubble" href="https:// | + | <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/project">LEARN MORE</a></p> |
</div> | </div> | ||
</div> | </div> | ||
Line 99: | Line 104: | ||
<div class="ch-item ch-img-3"> | <div class="ch-item ch-img-3"> | ||
<div class="ch-info"> | <div class="ch-info"> | ||
− | <h3 class="ch-bubble"> | + | <h3 class="ch-bubble">Parts</h3> |
− | <p class="ch-bubble">Cas9 | + | <p class="ch-bubble">Cas9 fusion proteins<br> |
− | <a class="ch-bubble" href="https:// | + | <a class="ch-bubble" href="https://2017.igem.org/Team:Northwestern/Parts">LEARN MORE</a></p> |
− | + | </div> | |
</div> | </div> | ||
</li> | </li> | ||
Line 110: | Line 115: | ||
</div> | </div> | ||
<div style="z-index:1 !important;" class="w3-display-bottommiddle"> | <div style="z-index:1 !important;" class="w3-display-bottommiddle"> | ||
− | <button style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small" onclick="scrollWin2()"> | + | <button height="80%" width="auto" style="position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin2()"> |
<span style="color:white;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | <span style="color:white;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | ||
</span> | </span> | ||
Line 116: | Line 121: | ||
</div> | </div> | ||
</div> | </div> | ||
− | |||
<div class="bgimg-3 w3-display-container" id="second"> | <div class="bgimg-3 w3-display-container" id="second"> | ||
− | <div style="padding: 10%;"> | + | <div style="padding: 5% 10%;"> |
− | <h3 style="black;" class="w3-center w3-padding-large">Project significance</h3><br> | + | <h3 style="black;" class="w3-center w3-padding-large"><br><br>Project significance</h3><br> |
− | <p style="padding-bottom:0; padding-right: 10%; padding-left:10%; black; font-size:14px;" class="big"> | + | <p style="padding-bottom:0; padding-right: 10%; padding-left:10%; black; font-size:14px;" class="big"> VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. <b>By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source</b>.<br><br> </p> |
+ | |||
+ | <figure> | ||
+ | <br><br><br> | ||
+ | <center><img src="https://static.igem.org/mediawiki/2017/c/c0/T--Northwestern--GlobePractices.png" width="350px" border="0"> | ||
+ | </center></figure> | ||
+ | |||
+ | |||
+ | |||
+ | |||
− | |||
<div style="z-index:1 !important;" class="w3-display-bottommiddle"> | <div style="z-index:1 !important;" class="w3-display-bottommiddle"> | ||
− | <button style="margin:0; padding:0; position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small" onclick="scrollWin3()"> | + | <button style="margin:0; padding:0; position:relative !important; z-index:1 !important;" class="icon-button w3-hide-small w3-hide-medium" onclick="scrollWin3()"> |
<span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | <span style="color:black;" class="w3-xxxlarge glyphicon glyphicon-chevron-down"> | ||
</span> | </span> | ||
Line 135: | Line 147: | ||
</div> | </div> | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<div class="w3-display-container"> | <div class="w3-display-container"> | ||
Line 151: | Line 155: | ||
</div> | </div> | ||
<div class="w3-center container"> | <div class="w3-center container"> | ||
− | <span class="w3-center"> <video class="w3-center" controls><source src= "https://static.igem.org/mediawiki/ | + | <span class="w3-center"> <video class="w3-center" controls><source src= "https://static.igem.org/mediawiki/2017/6/60/T--Northwestern--videofast.mp4" type="video/mp4" type="video/mp4"></video> </span> |
</div> | </div> | ||
</div> | </div> | ||
Line 171: | Line 175: | ||
</div> | </div> | ||
</div> | </div> | ||
+ | <br> | ||
+ | <br> | ||
</body> | </body> | ||
</html> | </html> | ||
{{Northwestern_Page_Foot_temp}} | {{Northwestern_Page_Foot_temp}} |
Latest revision as of 17:09, 20 November 2017
Engineering pathways for integrating functional Cas9 protein into OMVs
Inappropriate use of antibiotics has escalated the growing problem of antibiotic resistance in many threatening diseases. In 2014, the World Health Organization classified antibiotic resistance as a global epidemic. Inactivating resistance genes via Cas9 nuclease-mediated cleavage has been shown to be an effective means of combating this epidemic; however, methods of in vivo delivery are currently limited. Our team aims to deliver Cas9 to antibiotic-resistant, pathogenic bacteria through submicron bacterial outer membrane vesicles (OMVs) as a companion re-sensitization therapeutic to antibiotic treatment. OMVs are naturally produced by all Gram-negative bacteria and are used for crosstalk, stress responses, and nutrient acquisition. Their ability to be modified and directed with relative ease makes them an ideal carrier of CRISPR-Cas9. Aiding conventional antibiotic treatment, our technology will model a complete protein delivery system and transport functional Cas9 to target cells.
-
About us
Northwestern University iGEM
LEARN MORE -
Project description
Outer Membrane Vesicles
LEARN MORE -
Parts
Cas9 fusion proteins
LEARN MORE
Project significance
VesiCure aims to create a therapeutic delivery system for CRISPR gene-editing technology using bacterial outer-membrane vesicles (OMVs). We hope to be able to utilize this delivery system to target the antibiotic resistant genes in bacteria, thereby allowing antibiotic treatments to be effective by eliminating the adaptive ability of bacterial resistance. By genetically altering the resistant bacteria, this treatment would help combat the problem of antibiotic resistance directly from the source.